{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:08:49Z","timestamp":1769242129286,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13048-015-0124-8","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T17:28:03Z","timestamp":1423502883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population"],"prefix":"10.1186","volume":"8","author":[{"given":"Moria H","family":"Belanger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Dolman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanna L","family":"Arcand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Mes-Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia N","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"issue":"1","key":"124_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","volume":"23","author":"JD Seidman","year":"2004","unstructured":"Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41\u20134.","journal-title":"Int J Gynecol Pathol"},{"key":"124_CR2","unstructured":"NC I. Ovarian Epithelial Cancer Treatment (PDQ\u00ae). Bethesda, MA USA; 2012."},{"issue":"10","key":"124_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"124_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/IGC.0b013e31821b2669","volume":"21","author":"JA Ledermann","year":"2011","unstructured":"Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, et al. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer. 2011;21(4):763\u201370.","journal-title":"Int J Gynecol Cancer"},{"issue":"14","key":"124_CR5","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2011.1456","volume":"306","author":"D Yang","year":"2011","unstructured":"Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557\u201365.","journal-title":"JAMA"},{"issue":"6","key":"124_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","volume":"22","author":"PM Vencken","year":"2011","unstructured":"Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22(6):1346\u201352.","journal-title":"Ann Oncol"},{"issue":"15","key":"124_CR7","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1002\/cncr.26655","volume":"118","author":"DM Hyman","year":"2012","unstructured":"Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer. 2012;118(15):3703\u20139.","journal-title":"Cancer"},{"issue":"9","key":"124_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852\u201361.","journal-title":"Lancet Oncol"},{"issue":"2","key":"124_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"124_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10689-007-9152-x","volume":"6","author":"PN Tonin","year":"2007","unstructured":"Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer. 2007;6(4):491\u20137.","journal-title":"Fam Cancer"},{"issue":"12","key":"124_CR11","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/cncr.21536","volume":"104","author":"T Pal","year":"2005","unstructured":"Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807\u201316.","journal-title":"Cancer"},{"issue":"21","key":"124_CR12","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654\u201363.","journal-title":"J Clin Oncol"},{"issue":"3","key":"124_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","volume":"118","author":"D Vicus","year":"2010","unstructured":"Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, et al. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol. 2010;118(3):299\u2013302.","journal-title":"Gynecol Oncol"},{"issue":"44","key":"124_CR14","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"124_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","volume":"121","author":"S Zhang","year":"2011","unstructured":"Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121(2):353\u20137.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"124_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/jnci\/djs494","volume":"105","author":"JR McLaughlin","year":"2013","unstructured":"McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst. 2013;105(2):141\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"124_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/GCO.0b013e328332dca3","volume":"22","author":"AW Kurian","year":"2010","unstructured":"Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol. 2010;22(1):72\u20138.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"2 Pt 1","key":"124_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","volume":"120","author":"KA Schrader","year":"2012","unstructured":"Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. 2012;120(2 Pt 1):235\u201340.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"124_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y","volume":"16","author":"C Szabo","year":"2000","unstructured":"Szabo C, Masiello A, Ryan JF, Brody LC. The breast cancer information core: database design, structure, and scope. Hum Mutat. 2000;16(2):123\u201331.","journal-title":"Hum Mutat"},{"issue":"2","key":"124_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/ng1096-188","volume":"14","author":"CSJ Oddoux","year":"1996","unstructured":"Oddoux CSJ, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996;14(2):188\u201390.","journal-title":"Nat Genet"},{"issue":"2","key":"124_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14(2):185\u20137.","journal-title":"Nat Genet"},{"issue":"3","key":"124_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/1097-0215(20010520)95:3<189::AID-IJC1032>3.0.CO;2-N","volume":"95","author":"PN Tonin","year":"2001","unstructured":"Tonin PN, Perret C, Lambert JA, Paradis AJ, Kantemiroff T, Benoit MH, et al. Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. Int J Cancer. 2001;95(3):189\u201393.","journal-title":"Int J Cancer"},{"issue":"5645","key":"124_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MCMJ King","year":"2003","unstructured":"King MCMJ, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643\u20136.","journal-title":"Science"},{"issue":"4","key":"124_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10689-010-9372-3","volume":"9","author":"L Cavallone","year":"2010","unstructured":"Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, et al. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Fam Cancer. 2010;9(4):507\u201317.","journal-title":"Fam Cancer"},{"issue":"2","key":"124_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000053364","volume":"52","author":"AP Manning","year":"2001","unstructured":"Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, et al. Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered. 2001;52(2):116\u201320.","journal-title":"Hum Hered"},{"issue":"1","key":"124_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2350-7-23","volume":"7","author":"KK Oros","year":"2006","unstructured":"Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, et al. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and\/ovarian cancer families. BMC Med Genet. 2006;7(1):23.","journal-title":"BMC Med Genet"},{"issue":"3","key":"124_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ijc.20406","volume":"112","author":"KKGP Oros","year":"2004","unstructured":"Oros KKGP, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, et al. Significant proportion of breast and\/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer. 2004;112(3):411\u20139.","journal-title":"Int J Cancer"},{"issue":"2","key":"124_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/jmg.2006.044388","volume":"44","author":"J Simard","year":"2007","unstructured":"Simard J, Dumont M, Moisan AM, Gaborieau V, Malouin H, Durocher F, et al. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet. 2007;44(2):107\u201321.","journal-title":"J Med Genet"},{"issue":"5","key":"124_CR29","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1086\/302099","volume":"63","author":"PN Tonin","year":"1998","unstructured":"Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998;63(5):1341\u201351.","journal-title":"Am J Hum Genet"},{"key":"124_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev.genom.2.1.69","volume":"2","author":"CR Scriver","year":"2001","unstructured":"Scriver CR. Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet. 2001;2:69\u2013101.","journal-title":"Annu Rev Genomics Hum Genet."},{"issue":"4","key":"124_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1399-0004.2005.00497.x","volume":"68","author":"AM Laberge","year":"2005","unstructured":"Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, et al. Population history and its impact on medical genetics in Quebec. Clin Genet. 2005;68(4):287\u2013301.","journal-title":"Clin Genet"},{"issue":"9","key":"124_CR32","first-page":"841","volume":"93","author":"PN Tonin","year":"2006","unstructured":"Tonin PN. The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec. Canada Bull Cancer. 2006;93(9):841\u20136.","journal-title":"Canada. Bull Cancer."},{"issue":"2\u20133","key":"124_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00439-005-1297-9","volume":"117","author":"H Vezina","year":"2005","unstructured":"Vezina H, Durocher F, Dumont M, Houde L, Szabo C, Tranchant M, et al. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast\/ovarian cancer families. Hum Genet. 2005;117(2\u20133):119\u201332.","journal-title":"Hum Genet"},{"issue":"1","key":"124_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ygyno.2008.10.007","volume":"112","author":"KA Metcalfe","year":"2009","unstructured":"Metcalfe KA, Fan I, McLaughlin J, Risch HA, Rosen B, Murphy J, et al. Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study. Gynecol Oncol. 2009;112(1):68\u201372.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"124_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/cge.12313","volume":"86","author":"A Finch","year":"2014","unstructured":"Finch A, Bacopulos S, Rosen B, Fan I, Bradley L, Risch H, et al. Preventing ovarian cancer through genetic testing: a population-based study. Clin Genet. 2014;86(5):496\u20139.","journal-title":"Clin Genet"},{"issue":"5","key":"124_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1034\/j.1399-0004.1999.550504.x","volume":"55","author":"PN Tonin","year":"1999","unstructured":"Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet. 1999;55(5):318\u201324.","journal-title":"Clin Genet"},{"issue":"1","key":"124_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10549-011-1796-4","volume":"131","author":"S Cote","year":"2012","unstructured":"Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, et al. The BRCA2 c.9004G\u2009>\u2009A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and\/or ovarian cancer families of French Canadian descent. Breast Cancer Res Treat. 2012;131(1):333\u201340.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"124_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1158\/0008-5472.CAN-12-2081","volume":"73","author":"L Guidugli","year":"2013","unstructured":"Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, Engel C, et al. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res. 2013;73(1):265\u201375.","journal-title":"Cancer Res"},{"issue":"1","key":"124_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/jcp.55.1.27","volume":"55","author":"WG McCluggage","year":"2002","unstructured":"McCluggage WG, Lyness RW, Atkinson RJ, Dobbs SP, Harley I, McClelland HR, et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol. 2002;55(1):27\u201331.","journal-title":"J Clin Pathol"},{"issue":"1","key":"124_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/cge.12174","volume":"85","author":"P Ghadirian","year":"2014","unstructured":"Ghadirian P, Robidoux A, Nassif E, Martin G, Potvin C, Patocskai E, et al. Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal. Clin Genet. 2014;85(1):31\u20135.","journal-title":"Clin Genet"},{"issue":"2","key":"124_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"124_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1399-0004.2009.01277.x","volume":"76","author":"P Ghadirian","year":"2009","unstructured":"Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, et al. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet. 2009;76(5):421\u20136.","journal-title":"Clin Genet"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-015-0124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-015-0124-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-015-0124-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-015-0124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:03:56Z","timestamp":1630569836000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-015-0124-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1186\/s13048-015-0124-8","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]},"assertion":[{"value":"29 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"1"}}